Conclusions
This exploratory post-hoc analysis of a phase 3 clinical trial suggests that the introduction of AT II therapy at lower doses of vasopressor therapy may be associated with benefit. Prospective randomized trials of AT II infusion in lower NED patients may be both desirable and justified. While the data presented herein should be considered exploratory, hypothesis-generating, and should be interpreted with caution, they may inform selection of an appropriate threshold vasopressor dose below which introduction of AT II could be investigated.